Ebos lifted profit 21% in FY22 but analysts are asking how long it can last

Ebos lifted profit 21% in FY22 but analysts are asking how long it can last
Chief executive John Cullity said covid could be a tailwind or a headwind by the end of FY23. (Photo: Ebos)
Dan Brunskill
Ebos Group’s annual revenue has climbed above A$10 billion (NZ$11.15b) as the pandemic has increased demand for pharmaceutical products, but analysts are asking if that trend could reverse.  The healthcare and animal products company has been a beneficiary of the covid-19 pandemic, growing its revenue from A$8.7b in 2020 to A$10.7b in 2022.This year alone it grew revenue by 16.6%, underlying earnings by 19% and underlying net profit by 21.3% to A$228.2 million.Not all the growth has been driven by the pandemic however, Forsyth Barr r...

More Markets

Why does NZ suck at building brands
Markets

Eden Bradfield: Why does NZ suck at building brands

Let the French have Fonterra brands, Eden Bradfield writes.

Eden Bradfield 06 Sep 2025
NZ sharemarket ends week up 2.2%
Markets Market Close

NZ sharemarket ends week up 2.2%

The S&P/NZX 50 Index closed at 13,223.53, up 90.32 points or 0.69%.

Graham Skellern 05 Sep 2025
Fletcher Building slashes maximum CEO pay
Markets

Fletcher Building slashes maximum CEO pay

 Total maximum remuneration is now $2m lower at $5.8m.

Rebecca Howard 05 Sep 2025
Westpac NZ eyes monetary policy reform for change-laden RBNZ
Economy

Westpac NZ eyes monetary policy reform for change-laden RBNZ

Westpac NZ puts monetary policy voting in the spotlight.

Staff reporters 05 Sep 2025